Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 151 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

10%

15 trials in Phase 3/4

Results Transparency

3%

1 of 29 completed trials have results

Key Signals

34 recruiting1 with results

Enrollment Performance

Analytics

N/A
50(58.1%)
Phase 2
14(16.3%)
Phase 4
10(11.6%)
Phase 1
6(7.0%)
Phase 3
5(5.8%)
Early Phase 1
1(1.2%)
86Total
N/A(50)
Phase 2(14)
Phase 4(10)
Phase 1(6)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (151)

Showing 20 of 151 trials
NCT07570160Phase 4Not Yet Recruiting

Intranasal Dexmedetomidine or Esketamine for Negative Postoperative Behavioral Changes in Children

Role: collaborator

NCT05332496Completed

TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC

Role: lead

NCT05332821Completed

TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC

Role: lead

NCT06538883Not ApplicableRecruiting

Sedation in ICU Patients With Mechanical Ventilation

Role: lead

NCT07532538Not Yet Recruiting

A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions

Role: collaborator

NCT07324057Not ApplicableRecruiting

The Effects of Preoperative Intranasal Administration of Dexmedetomidine and Esketamine on Negative Postoperative Behavioral Changes in Children With Autism Spectrum Disorder

Role: collaborator

NCT04230785Recruiting

Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA)

Role: collaborator

NCT07516704Early Phase 1Not Yet Recruiting

Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study

Role: lead

NCT07504731Recruiting

Trunk Inclination, Positive End-expiratory Pressure, and Lung Recruitability

Role: lead

NCT07351669Recruiting

A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma

Role: lead

NCT07482137Not ApplicableRecruiting

Therapeutic Effect of Electroacupuncture at Zusanli (ST-36) on Diabetic Foot Wounds

Role: lead

NCT05475015Recruiting

3D-MRE for Assessing Cirrhosis, Advanced Chronic Liver Disease and Portal Hypertension

Role: collaborator

NCT06430554Recruiting

Personalized Ventilation Based on Ventilation-perfusion Mismatch and Lung Recruitability

Role: lead

NCT07337980Not Yet Recruiting

A Study on the Safety and Effectiveness of Endoscopic Intracavitary Submucosal Dissection for Gastric Extracavitary-Type Submucosal Tumors

Role: lead

NCT07311915Not ApplicableNot Yet Recruiting

Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in High-Risk Prostate Cancer Patients: A Multicenter, Single-Arm Clinical Study

Role: lead

NCT05348811Phase 2Completed

HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

Role: lead

NCT07268807Not Yet Recruiting

Effect of Roxadustat on Heart Failure Patients With Anaemia and Moderate-to-Severe Chronic Kidney Disease

Role: lead

NCT07024420Not ApplicableRecruiting

Sigh Ventilation in Cardiac Surgery

Role: lead

NCT07204327Active Not Recruiting

Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)

Role: lead

NCT07187284Phase 1Not Yet Recruiting

EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial

Role: lead